The Micron Pure™ device is designed to reduce airborne bacteria, viruses, and fungal spores to decrease infection rates from airborne pathogens. For this study, the Micron Pure™ device was challenged using aerosolized MS2 bacteriophage which has been historically used as a surrogate for influenza and is now being considered as a surrogate for coronaviruses such as COVID-19 due to the size similarity to influenza and RNA genome.
The CDC estimates that the influenza virus is responsible for 140,000 to 810,000 hospitalizations and 12,000 to 61,000 deaths annually. This study evaluated the efficacy of the device against aerosolized MS2 bacteriophage as well as various sizes of polystyrene latex microspheres (PSL) in a stainless steel bioaerosol chamber.
SANITIZING AIR AND SURFACES DOWN TO THE SUB-MICRON LEVEL
DECREASE INFECTION RATES
INACTIVATE AIRBORNE PATHOGENS
WHAT WE DO
WHAT WE DO
MICRON PURE™ is a technology created to inactivate airborne pathogens. Our patent-pending system powers the CerroZone™ device that recorded on live Sars-CoV-2 (COVID-19), showing a 99.9684% inactivation of virus particles on a single pass though the unit lasting less than 30 seconds and particulate reduction on the FDA proxy virus for SARS-CoV-2 (RNA virus MS2) of 99.999957% (6.57 LoG).
WHY IT MATTERS
WHY IT MATTERS
Micron Pure™ creates safe environments for working, learning, and community. Micron Pure™ reduces airborne contamination from person-to-person, periodically helps to inactivate pathogens left on objects that become airborne from an infected person. Complements measures already in place to lower the impact of COVID-19. Enhances the effectiveness of social distancing. Can help reduce infection while vaccines and medicines are developed and tested. Reduces Contamination. Increases protection for high risk and high contamination areas such as hospitals, nursing homes, airports, etc.
According to the CDC, there are now multiple SARS-CoV-2 variants circulating globally. These most notably include B.1.1.7 in the United Kingdom (UK), B.1.351 in South Africa, and P.1 in Brazil.
Ultraviolet light (UV) radiation from the range of wavelengths associated with UVC, UVB, and UVA has been shown to cause mutations across the SARS-CoV-2 genomes analyzed worldwide.
The B.1.1.7 mutated version quickly became the most common version of the coronavirus in the UK, accounting for about 60% of new COVID-19 cases in December of 2020.
Preliminary scientific evidence points to new variants, including B.1.1.7, binding more tightly to human cells. The effectiveness of currently authorized vaccines against these and new coronavirus variants is still being determined.